Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study.

Saved in:
Bibliographic Details
Title: Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study.
Authors: Ghafoor A; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Roper N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Kim C; Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia., Hoang CD; Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Kesarwala AH; Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Camphausen KA; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Farouq K; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Akoth E; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Keen C; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Szabo E; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.; Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Bhageri H; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland., Rajan A; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Guha U; Thoracic and Gastrointestinal Malignancies Branch (TGMB), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.; NextCure Inc., Clinical Development. Beltsville, Maryland.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2025 Aug 06; Vol. 6 (10), pp. 100886. Date of Electronic Publication: 2025 Aug 06 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3643
DOI:10.1016/j.jtocrr.2025.100886